BCG Vaccine
Biological
Merck Sharp & Dohme LLC
Total Payments
$37,697
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $37,697 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,697 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NA E HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER | Merck Sharp & Dohme LLC | $37,697 | 0 |
Top Doctors Receiving Payments for BCG Vaccine
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $37,697 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $37,697
Product Information
- Type Biological
- Total Payments $37,697
- Total Doctors 0
- Transactions 1
About BCG Vaccine
BCG Vaccine is a biological associated with $37,697 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme LLC.
Payment data is available from 2022 to 2022. In 2022, $37,697 was paid across 1 transactions to 0 doctors.
The most common payment nature for BCG Vaccine is "Unspecified" ($37,697, 100.0% of total).
BCG Vaccine is associated with 1 research study, including "A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NA E HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER" ($37,697).